Stuart Therapeutics
Stuart Therapeutics is a privately held, pre-revenue biotechnology company founded in 2017 that develops PolyCol, a proprietary therapeutic platform targeting ophthalmic indications, supported by a small clinical and research leadership team.
- Company typePrivate
- Founded2017
- HeadquartersStuart, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Stuart Therapeutics does
Stuart Therapeutics is a privately held biotechnology company founded in 2017 and headquartered in Stuart, United States. The company has developed PolyCol, a proprietary therapeutic platform focused on ophthalmic indications. The platform represents the core of Stuart Therapeutics' pipeline, addressing diseases of the eye through a targeted therapeutic approach.
The company operates with a small team of 1-10 employees and has assembled a leadership bench oriented around clinical and research execution. Eric Schlumpf serves as co-founder, President, and CEO; co-founder Shawn DeLorey leads Program Management and Corporate Development; Robert Baratta is Chairman, Chief Medical Officer, and Head of Product Development; Jodi Luchs serves as Chief Medical Officer; David Calkins is Chief Science Officer; Donald Stires is Chief Financial Officer; and Brian Del Buono serves as Executive Vice President of Research & Development. The presence of dual medical and scientific leadership roles indicates a focus on advancing programs from discovery through clinical development.
Stuart Therapeutics has raised $11,000,000 in a single disclosed funding round in March 2021, led by InFocus Capital Partners with participation from BioBrit, MiMo Capital, and the Wisconsin Alumni Research Foundation (WARF). The company operates as a pre-revenue clinical-stage biotech, and no commercial products, pricing models, partnership agreements, or revenue streams are disclosed in the available source data. Customer and revenue mechanics are not yet established, consistent with an early-stage therapeutic developer whose monetization pathway would typically involve licensing, partnership, or eventual commercialization.
Stuart Therapeutics firmographics
Firmographics- Name
- Stuart Therapeutics
- Website
- https://stuarttherapeutics.com
- Company type
- Private
- Founded year
- 2017
- Headcount range
- 1–10 employees
- Short description
- Stuart Therapeutics is a privately held, pre-revenue biotechnology company founded in 2017 that develops PolyCol, a proprietary therapeutic platform targeting ophthalmic indications, supported by a small clinical and research leadership team.
- Ownership category
- akta.pro rank
Stuart Therapeutics industry classification
Industry- Product category
- Ophthalmic Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industries
- Ophthalmology Pharmaceuticals (HLAIAAAL), Rare Ophthalmology Disorder Therapies (HLAIAIAK)
Keywords
Where Stuart Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Stuart
- HQ country
- United States
- HQ region
- North America
Markets served
Stuart Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Stuart Therapeutics product offering
Product offeringCore offering
Stuart Therapeutics is a biotechnology company developing PolyCol, a proprietary therapeutic platform for ophthalmic (eye) indications. The company focuses on leveraging this platform to discover and advance drug candidates targeting ocular diseases. Operations are centered on preclinical and clinical-stage research for eye-related therapeutic products.
Differentiator
Problem solved
Functional benefit
Products and services
- PolyCol Therapeutic Platform
Companies that use Stuart Therapeutics
Customer profileIdeal customer profiles1 record
Stuart Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Stuart Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Stuart Therapeutics competitors and assessment
Company assessmentDirect peers
- Clearside Biomedical: Ophthalmology-focused biopharmaceutical company developing therapeutics delivered via the suprachoroidal space for retinal and choroidal diseases, comparable as a small ophthalmology specialty developer with proprietary delivery technology.
- Kala Pharmaceuticals: Specialty ophthalmology pharmaceutical company developing therapeutics for ocular surface and retinal diseases, directly comparable as another focused ophthalmic therapeutics developer competing for similar indications and partnerships.
- Ocular Therapeutix: Ophthalmology specialty pharma developing therapies for retinal diseases and ocular surface conditions using proprietary drug delivery approaches; comparable platform-driven ophthalmic developer with both approved and pipeline assets.
- Aldeyra Therapeutics: Clinical-stage biotechnology company developing novel treatments for inflammatory ocular diseases, providing a directly comparable ophthalmology-focused development model with platform technology across multiple indications.
- EyePoint Pharmaceuticals: Specialty pharmaceutical company focused on ophthalmic and retinal diseases using sustained-release drug delivery technologies, comparable as a focused ophthalmology therapeutic developer with approved products.
Broad incumbents
- Aerie Pharmaceuticals: Commercial-stage ophthalmology pharmaceutical company with approved glaucoma products and additional pipeline assets; broader in scale and commercialization stage, but directly comparable in therapeutic focus area.
- REGENXBIO: Clinical-stage biotechnology company with a leading ophthalmology gene therapy program (ABBVIE collaboration), comparable as a platform gene therapy developer whose ocular programs represent directly overlapping therapeutic targets.
Emerging players
- Lexeo Therapeutics: Clinical-stage gene therapy company focused on ophthalmic and cardiac diseases, comparable as a small platform-driven developer targeting inherited and age-related ocular disorders.
- ProQR Therapeutics: Clinical-stage biotechnology company developing RNA-based therapeutics for genetic eye diseases and other conditions, providing comparability as an ophthalmology-focused developer using a novel therapeutic modality.
- Applied Genetic Technologies Corporation: Clinical-stage biotechnology company developing genetic therapies for rare ophthalmic diseases, comparable as a small-cap ophthalmology-focused developer with platform technology targeting multiple ocular indications.
Market position
Strengths4 records
Weaknesses3 records
Competitive moat2 records
Key risks4 records
Key highlights4 records
Customer concentration
Stuart Therapeutics social profiles
Digital presenceStuart Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stuart Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Stuart Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stuart Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stuart Therapeutics
What does Stuart Therapeutics do?
Stuart Therapeutics is a biotechnology company developing PolyCol, a proprietary therapeutic platform for ophthalmic (eye) indications. The company focuses on leveraging this platform to discover and advance drug candidates targeting ocular diseases. Operations are centered on preclinical and clinical-stage research for eye-related therapeutic products.
When was Stuart Therapeutics founded?
Stuart Therapeutics was founded in 2017. It employs 1 to 10 people.
Where is Stuart Therapeutics based?
Stuart Therapeutics is headquartered in Stuart, United States, in the North America region.
Who are Stuart Therapeutics's main competitors?
Direct peers on record are Clearside Biomedical, Kala Pharmaceuticals, Ocular Therapeutix, Aldeyra Therapeutics and EyePoint Pharmaceuticals. Broad incumbents are Aerie Pharmaceuticals and REGENXBIO. Emerging players are Lexeo Therapeutics, ProQR Therapeutics and Applied Genetic Technologies Corporation.
Does Stuart Therapeutics have an API?
No public API is recorded for Stuart Therapeutics.
What industry is Stuart Therapeutics in?
Stuart Therapeutics's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.